The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Long COVID is a debilitating chronic condition that has affected over 100 million people globally
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
Subscribe To Our Newsletter & Stay Updated